第二代抗精神病药物在治疗精神分裂症及相关障碍方面的疗效是否存在差异？
Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
作者信息
Motlová Lucie, Spaniel Filip, Höschl Cyril, Balon Richard
机构信息
Prague Psychiatric Centre, Centre of Neuropsychiatric Studies and Charles University, 3rd Medical Faculty, Prague, Czech Republic.
出版信息
Ann Clin Psychiatry. 2007 Apr-Jun;19(2):133-43. doi: 10.1080/10401230701334606.
BACKGROUND
The goal of this review is to summarize the results of head to head efficacy studies that compare second generation antipsychotics in the treatment of schizophrenia and related disorders.
METHODS
A literature search through the Medline database and Google was conducted. Articles published up to September 2005 were included. Abstracts from conference papers and posters were not included.
RESULTS
Randomized controlled trial data on possible differences in efficacy among atypical antipsychotics are limited. Moreover, the comparison is difficult, as studies differ in outcome measures. The results indicate that first-line second-generation antipsychotics (amisulpride, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone and zotepine) show comparable efficacy.
CONCLUSION
Possible new studies should focus on long-term effects, including cost-effectiveness, quality of life, social functioning and service utilization.
背景
本综述的目的是总结直接比较第二代抗精神病药物治疗精神分裂症及相关障碍疗效的研究结果。
方法
通过Medline数据库和谷歌进行文献检索。纳入截至2005年9月发表的文章。会议论文和海报的摘要不纳入。
结果
关于非典型抗精神病药物疗效可能存在差异的随机对照试验数据有限。此外，由于研究的结局指标不同，比较困难。结果表明，一线第二代抗精神病药物（氨磺必利、阿立哌唑、奥氮平、喹硫平、利培酮、齐拉西酮和佐替平）显示出相当的疗效。
结论
未来可能的新研究应关注长期影响，包括成本效益、生活质量、社会功能和服务利用。
Zotero 插件